neoantigen reactive T cells

Neoantigen reactive T cells (NRTs) are a form of autologous adoptive cell therapy designed to target tumor-specific mutations, known as neoantigens, which are unique to an individual patient's cancer. Unlike traditional tumor-infiltrating lymphocyte (TIL) therapy, which utilizes a bulk population of T cells from the tumor microenvironment, NRT therapy involves the precise identification of somatic mutations via next-generation sequencing (NGS) and the subsequent selection or engineering of T cells that specifically recognize these neoepitopes. This approach aims to enhance the specificity and potency of the anti-tumor immune response while minimizing off-target toxicity to healthy tissues. NRTs are frequently investigated in combination with individualized neoantigen vaccines or immune checkpoint inhibitors, such as PD-1 inhibitors, to improve T-cell persistence and overcome the immunosuppressive nature of advanced malignancies.

Other names

neoantigen-reactive T cellsneoantigen reactive T cells (NRTs)